Evidence map›Paper›PMID 32222169›Full record

ArticleThe Lancet. Respiratory medicine2020

Antihypertensive drugs and risk of COVID-19? - Authors' reply.

Lei Fang, George Karakiulakis, Michael Roth

Abstract readLetterComment
In one paragraph

Article in The Lancet. Respiratory medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed.

  1. Review
  2. Review
  3. COVID-19 in pregnancy: possible mechanisms not to be discounted.The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians · 2022
    Article
  4. Review
  5. Updates on Palliative Medicine in the COVID-19 Era.Journal of clinical medicine · 2022
    Article
  6. Article
  7. Review
  8. Analgesic Drugs and COVID-19.Journal of clinical medicine · 2021
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome.Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi · 2020
    Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Lei FangPulmonary Cell Research and Pneumology, Department of Biomedicine and Internal Medicine, University Hospital Basel, CH-4031 Basel, Switzerland.
George KarakiulakisDepartment of Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Michael RothPulmonary Cell Research and Pneumology, Department of Biomedicine and Internal Medicine, University Hospital Basel, CH-4031 Basel, Switzerland. Electronic address: michael.roth@usb.ch.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Diabetes MellitusHypertensionAntihypertensive AgentsBetacoronavirusCoronavirus InfectionsCOVID-19HumansPandemicsPneumonia, ViralSARS-CoV-2Antihypertensive Agents

Identifiers

PMID32222169
PMCPMC7194912

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.